ICER and Unsupported Price Increases

The Institute for Clinical and Economic Review (ICER) recently announced that it would annually review treatments with significant price increases to determine if these changes are unsupported by evidence on value. I was recently interviewed by Radar on Specialty Pharmacy to discuss the topic. Jason Shafrin, Ph.D., a senior director of policy and economics at…

Measuring caregiver quality of life

Poor health does not just affect the patient, but also the caregiver who provide physicial, emotional and financial support for these patients. To measure the impact of a disease on patient quality of life, there are a number of metrics one can choose from such as EQ-5D-5L, EQ-5D-VAS, SF-36 among others. Some of these surveys…

New IVI Report Examines Imbalances in Health Care Effectiveness Analyses

The Innovation and Value Initiative (IVI) – a collaboration of academics, patient advocacy organizations, payers, life sciences companies, providers, delivery systems, and other organizations dedicated to finding scientifically credible approaches to measuring value in health care – today released a report examining imbalances in cost-effectiveness analyses (CEAs) across pharmaceuticals, medical/surgical treatments, and mixed procedures. The report, Expanding Cost-Effectiveness…

Does preventive care save money?

Aaron Carroll argues ‘no’ and–in most but not all cases–I agree with him.  Here is the evidence he cites: More health insurance does not reduce emergency department (ED) visits.  States that expanded Medicaid eligibility with ACA funding saw an increase in ED visits relative to non-expansion states.  In Oregon, individuals who won an eligibility ‘lottery’ to…